Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Basal Cell | 4 | 2024 | 560 | 0.980 |
Why?
|
Skin Neoplasms | 7 | 2024 | 5821 | 0.890 |
Why?
|
Eyelid Neoplasms | 1 | 2023 | 89 | 0.810 |
Why?
|
Sweat Glands | 1 | 2022 | 33 | 0.800 |
Why?
|
Dermatology | 4 | 2022 | 918 | 0.670 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2023 | 4026 | 0.560 |
Why?
|
Hyperbilirubinemia | 1 | 2015 | 74 | 0.510 |
Why?
|
Glucuronosyltransferase | 1 | 2015 | 132 | 0.500 |
Why?
|
RNA Splice Sites | 1 | 2015 | 211 | 0.480 |
Why?
|
Carcinoma | 1 | 2022 | 2330 | 0.360 |
Why?
|
Exons | 1 | 2015 | 2391 | 0.340 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 3201 | 0.330 |
Why?
|
Primary Health Care | 1 | 2024 | 4686 | 0.290 |
Why?
|
Appointments and Schedules | 2 | 2020 | 443 | 0.260 |
Why?
|
Melanoma | 1 | 2024 | 5709 | 0.250 |
Why?
|
Genome, Viral | 2 | 2019 | 667 | 0.240 |
Why?
|
Promoter Regions, Genetic | 1 | 2015 | 5789 | 0.230 |
Why?
|
Quackery | 1 | 2021 | 6 | 0.200 |
Why?
|
Internship and Residency | 1 | 2022 | 5880 | 0.200 |
Why?
|
Computers, Handheld | 1 | 2024 | 210 | 0.200 |
Why?
|
Parainfluenza Virus 1, Human | 1 | 2019 | 25 | 0.170 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2019 | 25 | 0.170 |
Why?
|
Neoplasm Staging | 3 | 2023 | 11121 | 0.160 |
Why?
|
Equipment and Supplies | 1 | 2021 | 273 | 0.160 |
Why?
|
Hair | 1 | 2021 | 498 | 0.150 |
Why?
|
Adenovirus Infections, Human | 1 | 2018 | 73 | 0.140 |
Why?
|
Hedgehog Proteins | 1 | 2022 | 768 | 0.140 |
Why?
|
Alopecia | 1 | 2021 | 412 | 0.140 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2021 | 1241 | 0.130 |
Why?
|
Commerce | 1 | 2021 | 606 | 0.130 |
Why?
|
Adenoviruses, Human | 1 | 2018 | 255 | 0.130 |
Why?
|
Schools, Medical | 1 | 2022 | 879 | 0.130 |
Why?
|
Office Visits | 1 | 2019 | 595 | 0.130 |
Why?
|
Waiting Lists | 1 | 2020 | 765 | 0.120 |
Why?
|
Prognosis | 4 | 2023 | 29625 | 0.120 |
Why?
|
Radiotherapy | 1 | 2022 | 1499 | 0.120 |
Why?
|
Lymphatic Metastasis | 1 | 2022 | 2915 | 0.110 |
Why?
|
Bilirubin | 1 | 2015 | 436 | 0.110 |
Why?
|
Homozygote | 2 | 2015 | 1776 | 0.110 |
Why?
|
Neoplasm Invasiveness | 1 | 2022 | 3595 | 0.110 |
Why?
|
Organ Transplantation | 1 | 2023 | 1157 | 0.110 |
Why?
|
Genomics | 2 | 2019 | 5821 | 0.100 |
Why?
|
Lymph Nodes | 2 | 2023 | 3466 | 0.100 |
Why?
|
Heterozygote | 2 | 2015 | 2787 | 0.100 |
Why?
|
Humans | 23 | 2024 | 761504 | 0.090 |
Why?
|
Income | 1 | 2019 | 1877 | 0.090 |
Why?
|
DNA, Viral | 1 | 2018 | 2202 | 0.090 |
Why?
|
Pilot Projects | 1 | 2024 | 8631 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2022 | 1922 | 0.090 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2373 | 0.090 |
Why?
|
Combined Modality Therapy | 1 | 2022 | 8529 | 0.080 |
Why?
|
Retrospective Studies | 6 | 2024 | 80636 | 0.080 |
Why?
|
Internet | 1 | 2021 | 3092 | 0.080 |
Why?
|
Incidental Findings | 1 | 2014 | 697 | 0.080 |
Why?
|
India | 1 | 2015 | 2348 | 0.080 |
Why?
|
Sensitivity and Specificity | 1 | 2024 | 14666 | 0.080 |
Why?
|
Stroke Volume | 2 | 2021 | 5496 | 0.080 |
Why?
|
Hospitals | 1 | 2021 | 3882 | 0.080 |
Why?
|
Insurance, Health | 1 | 2020 | 2498 | 0.070 |
Why?
|
Heart Rate | 1 | 2018 | 4195 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2015 | 2571 | 0.070 |
Why?
|
Heart Failure | 2 | 2021 | 11669 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 15936 | 0.060 |
Why?
|
Cohort Studies | 3 | 2024 | 41487 | 0.060 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1551 | 0.060 |
Why?
|
Cholera | 1 | 2011 | 747 | 0.060 |
Why?
|
Communicable Disease Control | 1 | 2011 | 846 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26125 | 0.060 |
Why?
|
Recombination, Genetic | 2 | 2019 | 1519 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2022 | 9280 | 0.060 |
Why?
|
Philadelphia | 1 | 2023 | 266 | 0.050 |
Why?
|
Risk Assessment | 1 | 2024 | 23995 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5440 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2019 | 6346 | 0.050 |
Why?
|
Disease Outbreaks | 1 | 2011 | 1749 | 0.050 |
Why?
|
Ohio | 1 | 2022 | 322 | 0.050 |
Why?
|
Algorithms | 3 | 2020 | 14031 | 0.050 |
Why?
|
Female | 6 | 2024 | 392644 | 0.050 |
Why?
|
Fraud | 1 | 2021 | 66 | 0.050 |
Why?
|
Genome, Human | 1 | 2014 | 4425 | 0.050 |
Why?
|
Phylogeny | 2 | 2019 | 2811 | 0.050 |
Why?
|
Mutation | 2 | 2015 | 30052 | 0.040 |
Why?
|
Evolution, Molecular | 2 | 2019 | 1886 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2019 | 6935 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2022 | 13639 | 0.040 |
Why?
|
Male | 6 | 2024 | 360804 | 0.040 |
Why?
|
Middle Aged | 3 | 2024 | 220895 | 0.040 |
Why?
|
Geography | 1 | 2019 | 656 | 0.040 |
Why?
|
Adult | 3 | 2024 | 221177 | 0.040 |
Why?
|
Sequence Analysis, DNA | 2 | 2019 | 4740 | 0.040 |
Why?
|
Ventricular Function, Right | 1 | 2021 | 617 | 0.040 |
Why?
|
Aged | 3 | 2024 | 169289 | 0.030 |
Why?
|
Telephone | 1 | 2019 | 627 | 0.030 |
Why?
|
Selection, Genetic | 1 | 2019 | 868 | 0.030 |
Why?
|
Family Characteristics | 1 | 2019 | 1004 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2019 | 3639 | 0.030 |
Why?
|
Observer Variation | 1 | 2019 | 2606 | 0.030 |
Why?
|
Adolescent | 2 | 2022 | 88319 | 0.020 |
Why?
|
Educational Status | 1 | 2019 | 2522 | 0.020 |
Why?
|
Molecular Sequence Annotation | 1 | 2014 | 522 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2014 | 957 | 0.020 |
Why?
|
Logistic Models | 2 | 2018 | 13255 | 0.020 |
Why?
|
Mutagenesis, Insertional | 1 | 2014 | 656 | 0.020 |
Why?
|
Propensity Score | 1 | 2018 | 1913 | 0.020 |
Why?
|
Haiti | 1 | 2011 | 550 | 0.020 |
Why?
|
Young Adult | 1 | 2015 | 59243 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4915 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 39967 | 0.020 |
Why?
|
Base Sequence | 1 | 2018 | 12441 | 0.020 |
Why?
|
Pedigree | 1 | 2014 | 4542 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10766 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2024 | 58976 | 0.020 |
Why?
|
Computational Biology | 1 | 2018 | 3518 | 0.020 |
Why?
|
Genotype | 1 | 2018 | 12990 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13506 | 0.010 |
Why?
|
United States | 2 | 2021 | 72334 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10723 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 20098 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2024 | 13380 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2014 | 16981 | 0.010 |
Why?
|
Risk Factors | 1 | 2023 | 74206 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21353 | 0.010 |
Why?
|
Concepts
(122)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(29)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_